Biopharma & Life Sciences
Zymeworks Executive Compensation (FY24)
ZYME · Executive and director compensation, fiscal 2023 to 2024
Data as of September 7, 2026Latest filing (8-K): December 30, 2025
126 figures on this page: 122 cited to the filing that reported them, 4 calculated from figures it prints. See the citations
Kenneth Galbraith, Chief Executive Officer, President and Chair of Board of Directors, received $5,253,616 in total compensation for fiscal 2024, and Galbraith's total was 55.7% higher than the $3,374,876 reported for fiscal 2023. The say-on-pay proposal drew 94.1% of votes cast for or against in favor at the meeting held December 30, 2025 for fiscal 2024. The disclosed peer group names Adaptimmune Therapeutics plc, Alector, Inc., AnaptysBio, Inc., Atara Biotherapeutics, Inc. and Bicycle Therapeutics, among others. For fiscal 2024, the company reported 3 named executive officers.
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Kenneth Galbraith: $3,374,876 → $5,253,616 (55.7% higher)
Say-on-pay support: 93.5% → 94.1% (0.6 points higher)
Frequently asked questions
Answers drawn from the data on this page.
Who is Zymeworks' chief executive and what were they paid?
Kenneth Galbraith, Chief Executive Officer, President and Chair of Board of Directors, received $5,253,616 in total compensation for fiscal 2024. Galbraith's total was 55.7% higher than the $3,374,876 reported for fiscal 2023.
What was Zymeworks' say-on-pay result?
The say-on-pay proposal drew 94.1% of votes cast for or against in favor at the meeting held December 30, 2025 for fiscal 2024.
Which companies are in Zymeworks' peer group?
The disclosed peer group names Adaptimmune Therapeutics plc, Alector, Inc., AnaptysBio, Inc., Atara Biotherapeutics, Inc. and Bicycle Therapeutics, among others.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Kenneth Galbraith Chief Executive Officer, President and Chair of Board of Directors | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Paul Moore Chief Scientific Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Kenneth Galbraith Chief Executive Officer, President and Chair of Board of Directors | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Leone Patterson Executive Vice President, Chief Business Officer and Chief Financial Officer | ◇ | ◇ | — | ◇ | ◇ | — | ◇ | ◇ |
Paul Moore Chief Scientific Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2024
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Kenneth Galbraith | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Kenneth Galbraith | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Leone Patterson | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Paul Moore | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Paul Moore | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
Fiscal 2022, 2023 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Paul Moore | Option | ◇ | — | ◇ | 1/4/2034 |
| Option | ◇ | — | ◇ | 1/4/2033 | |
| Option | ◇ | — | ◇ | 7/17/2032 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Leone Patterson | Option | ◇ | — | ◇ | 8/31/2034 |
| Kenneth Galbraith | Option | ◇ | — | ◇ | 1/4/2034 |
| Option | ◇ | — | ◇ | 1/4/2033 | |
| Option | ◇ | — | ◇ | 1/14/2032 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2024
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Alessandra Cesano | ◇ | — | ◇ | — | — | — | ◇ |
Neil Gallagher | ◇ | — | ◇ | — | — | — | ◇ |
Susan Mahony Lead independent director | ◇ | — | ◇ | — | — | — | ◇ |
Carlos Campoy | ◇ | — | ◇ | — | — | — | ◇ |
Derek J. Miller | ◇ | — | ◇ | — | — | — | ◇ |
Kelvin Neu | ◇ | — | ◇ | — | — | — | ◇ |
Nancy Davidson | ◇ | — | ◇ | — | — | — | ◇ |
Troy M. Cox | ◇ | — | ◇ | — | — | — | ◇ |
Hollings C. Renton | ◇ | — | — | — | — | — | ◇ |
Kenneth Hillan | ◇ | — | — | — | — | — | ◇ |
Scott Platshon, Oleg Nodelman, Kenneth Galbraith, Robert E. Landry and Gregory A. Ciongoli served on the board in fiscal 2024 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Options.
Stock ownership guideline: The compensation committee subsequently recommended, and the Board of Directors approved, the adoption of stock ownership guidelines for non-management directors in August 2025 and September 2025, respectively, as further described in the section of this Proxy Statement entitled “Governance – Stock Ownership Guidelines”.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2024
- Adaptimmune Therapeutics plc ADAP
- Alector, Inc. ALEC
- AnaptysBio, Inc. ANAB
- Atara Biotherapeutics, Inc. ATRA
- Bicycle Therapeutics BCYC
- C4 Therapeutics CCCC
- Cogent Biosciences COGT
- Gossamer Bio, Inc. GOSS
- IGM Biosciences, Inc. IGMS
- Iteos Therapeutics ITOS
- Jounce Therapeutics, Inc. symbol not shown
- Kura Oncology, Inc. KURA
- MacroGenics, Inc. MGNX
- Mersana Therapeutics, Inc. MRSN
- NGM Biopharmaceuticals, Inc. NGM
- Poseida Therapeutics, Inc. PSTX
- Precision Biosciences DTIL
- REGENXBIO Inc. RGNX
- Relay Therapeutics RLAY
- Repare Therapeutics Inc. RPTX
- Replimune Group, Inc. REPL
- Sutro Biopharma, Inc. STRO
- Xencor XNCR
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2024 | December 30, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | December 10, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | December 7, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | December 16, 2022 | = | ◇ | ◇ | ◇ |
What this page does not include
Everything above is a fact Zymeworks disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Zymeworks sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
126 figures on this page: 122 cited to the filing that reported them, 4 calculated from figures it prints.
122 cited to the filing
4 calculated from the filing
Documents cited
- 0001193125-25-337268Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-25-274338DIRECTOR COMPENSATION · Grants of Plan-Based Awards · Outstanding Equity Awards at 2024 Year End · Summary Compensation Table
- 0001193125-24-275534Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-23-291692Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-22-308358Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Zymeworks executive compensation, FY2023–FY2024.” https://intel.velarion.ai/comp/ZYME (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Zymeworks and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Peers Zymeworks discloses
The companies named in ZYME's own disclosed peer group.
Terms on this page
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}